KZIA — Kazia Therapeutics Share News
0.000.00%
Last trade - 00:00- $0.07m
- -$38.66m
- AU$0.11m
Kazia Therapeutics soars as breast cancer therapy disrupts tumor cell clusters
Brief: Kazia Therapeutics Announces $2 Million Private Placement At Premium To Market
Brief: Kazia Therapeutics Announces Transformative Preclinical Data
Brief: Kazia Therapeutics Announces First Patient Dosed In Phase 1B Trial Of Paxalisib In Advanced Breast Cancer
Brief: Kazia Therapeutics-Plans To Change Ratio Of Its Adss To Ordinary Shares To One ADS Representing 500 Ordinary Shares
U.S. STOCKS ON THE MOVE-Comm services, Nvidia, US insurers
U.S. STOCKS ON THE MOVE-Boeing, US banks, Flagstar Financial
Brief: Kazia Therapeutics Provides Update On Paxalisib Regulatory Pathway Following Type C Meeting With FDA
Kazia Therapeutics falls after US FDA says cancer drug cannot be granted accelerated approval
Brief: Kazia Therapeutics Announces Granting Of Type C Meeting With FDA To Discuss Potential Next Steps For Paxalisib In The Treatment Of Newly Diagnosed Glioblastoma Multiforme
Brief: Kazia Therapeutics Says Plan To Change Ratio Of ADSs To One ADS Representing 100 Ordinary Shares
Brief: Kazia Executes Licensing Agreement With QIMR Berghofer
Kazia gains as brain cancer drug increases survival in mid-to-late stage study
Brief: Kazia Therapeutics Entered Into Purchase Agreement With Alumni Capital
Brief: Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint
Brief: Kazia Therapeutics Files Prospectus For Resale of ADS By Selling Shareholders
Brief: Kazia Therapeutics Enters Collaboration With Australian And NZ Children's Haematology/Oncology Group
Kazia up on promising interim data from brain tumor study
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:22 PM